Company Monitoring Page for ViiV-Healthcare

latest headlines for company on cafepharma

GSK's ViiV Healthcare continues cabaret campaign to engage and inspire HIV community
Fierce Pharma
Thu, 04/8/21 - 07:35 pm
Tags:
pharma marketing, GSK, ViiV Healthcare, HIV
ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults
Pharmaceutical Business Review
Thu, 02/25/21 - 09:50 am
Tags:
ViiV Healthcare, FDA, Cabenuva, HIV-1
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato
Pharmaceutical Business Review
Fri, 08/7/20 - 10:40 am
Tags:
ViiV Healthcare, FDA, HIV, Dovato, HIV-1
GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada
Endpoints
Wed, 07/8/20 - 10:38 am
Tags:
GSK, Gilead Sciences, ViiV Healthcare, HIV, cabotegravir, Truvada
GSK snags first-in-class FDA nod for Rukobia to treat HIV patients who have few options
Fierce Pharma
Tue, 07/7/20 - 10:37 am
Tags:
GSK, ViiV Healthcare, Rukobia, fostemsavir, HIV, FDA
ViiV Healthcare gets FDA nod for HIV drug Rukobia to treat adult patients
Pharmaceutical Business Review
Fri, 07/3/20 - 01:05 pm
Tags:
ViiV Healthcare, FDA, Rukobia, HIV
FDA approves dispersible tablet formulation of dolutegravir for HIV in children
Pharmaceutical Business Review
Mon, 06/15/20 - 10:56 am
Tags:
ViiV Healthcare, FDA, Tivicay, pediatric
GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
Endpoints
Tue, 05/19/20 - 10:33 am
Tags:
GSK, Gilead Sciences, HIV, PrEP, Truvada, ViiV Healthcare, cabotegravir
ViiV’s two-drug HIV therapy Dovato gets Japanese approval
Pharmaforum
Thu, 01/16/20 - 11:02 pm
Tags:
ViiV Healthcare, Dovato, HIV, Japan
ViiV files first-in-class HIV drug in Europe
Pharmaforum
Mon, 01/13/20 - 10:23 am
Tags:
ViiV Healthcare, Europe, HIV, fostemsavir
GSK's plan to take over the HIV drug market hasn't worked out
BioPharma Dive
Mon, 01/6/20 - 11:47 pm
Tags:
GSK, FDA, HIV, Dovato, Biktarvy, ViiV Healthcare, Gilead Sciences
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavir
Pharmaforum
Fri, 12/6/19 - 10:02 am
Tags:
ViiV Healthcare, HIV, fostemsavir, FDA
ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment
Pharmaceutical Business Review
Fri, 11/22/19 - 10:02 am
Tags:
HIV, NIH, ViiV Healthcare, HIV-1, drug discovery
GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors
Fierce Pharma
Wed, 10/9/19 - 09:49 am
Tags:
GSK, ViiV Healthcare, Dovato, DTC ads, HIV
GSK's ViiV reports positive data for long-acting two-drug HIV therapy
Biopharma Dive
Thu, 08/22/19 - 11:46 am
Tags:
ViiV Healthcare, GSK, HIV, cabotegravir, rilpivirine
ViiV’s first-in-class HIV drug on course for filings this year
Pharmaforum
Tue, 07/23/19 - 10:16 am
Tags:
ViiV Healthcare, HIV, fostemsavir, FDA
ViiV's HIV Drug Hits Endpoints in Late-Stage Comparison Trial
BioSpace
Wed, 07/10/19 - 10:18 am
Tags:
GSK, ViiV Healthcare, Dovato, HIV
ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment
Pharmaceutical Business Review
Tue, 07/9/19 - 08:51 am
Tags:
ViiV Healthcare, HIV, cabotegravir, rilpivirine
ViiV Submits NDA for Once-Per-Month HIV Injectable
BioSpace
Mon, 04/29/19 - 08:54 pm
Tags:
ViiV Healthcare, FDA, HIV, HIV-1, cabotegravir, rilpivirine
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
Pharmaceutical Business Review
Thu, 04/4/19 - 11:58 am
Tags:
ViiV Healthcare, Dolutegravir, rilpivirine, JNJ, Janssen, HIV

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.